137 related articles for article (PubMed ID: 16799637)
1. Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.
Yang G; Thompson MA; Brandt SJ; Hiebert SW
Oncogene; 2007 Jan; 26(1):91-101. PubMed ID: 16799637
[TBL] [Abstract][Full Text] [Related]
2. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Wang J; Saunthararajah Y; Redner RL; Liu JM
Cancer Res; 1999 Jun; 59(12):2766-9. PubMed ID: 10383127
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Sasaki K; Yamagata T; Mitani K
Cancer Sci; 2008 Feb; 99(2):414-22. PubMed ID: 18271940
[TBL] [Abstract][Full Text] [Related]
5. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
6. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
Yan M; Kanbe E; Peterson LF; Boyapati A; Miao Y; Wang Y; Chen IM; Chen Z; Rowley JD; Willman CL; Zhang DE
Nat Med; 2006 Aug; 12(8):945-9. PubMed ID: 16892037
[TBL] [Abstract][Full Text] [Related]
7. The 8;21 translocation in leukemogenesis.
Peterson LF; Zhang DE
Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
[TBL] [Abstract][Full Text] [Related]
8. Translocation (8;21)(q22;q22) without rearrangement of RUNX1 and RUNX1T1 genes in a patient with refractory anemia with excess of blasts.
Aguilar A; Talavera M; Villalon C; Garcia-Sagredo JM; de Leon A; Sordo T; Cabello P; Gonzalez FA; Garcia-Galloway E; San Roman C; Ferro T
Cancer Genet Cytogenet; 2008 Jan; 180(1):85-6. PubMed ID: 18068542
[No Abstract] [Full Text] [Related]
9. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?
Deluche L; Joha S; Corm S; Daudignon A; Geffroy S; Quief S; Villenet C; Kerckaert JP; Laï JL; Preudhomme C; Roche-Lestienne C
Genes Chromosomes Cancer; 2008 Dec; 47(12):1110-7. PubMed ID: 18767145
[TBL] [Abstract][Full Text] [Related]
10. Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).
Sakai I; Tamura T; Narumi H; Uchida N; Yakushijin Y; Hato T; Fujita S; Yasukawa M
Genes Chromosomes Cancer; 2005 Nov; 44(3):265-70. PubMed ID: 16015645
[TBL] [Abstract][Full Text] [Related]
11. Variant translocation t(2;21;8)(q36;q22;q22) with RUNX1/CBFA2T1 (AML1/ETO) transcript in a case of acute myelogenous leukemia.
Hsiao HH; Sashida G; Kodama A; Fukutake K; Ohyashiki K
Cancer Genet Cytogenet; 2005 May; 159(1):96-7. PubMed ID: 15860366
[No Abstract] [Full Text] [Related]
12. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
[TBL] [Abstract][Full Text] [Related]
13. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
14. MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).
Kozu T; Fukuyama T; Yamami T; Akagi K; Kaneko Y
Genes Chromosomes Cancer; 2005 May; 43(1):45-53. PubMed ID: 15723339
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic regulation of tumor suppressors in t(8:21)-containing AML.
Yang G; Khalaf W; van de Locht L; Jansen JH; van der Reijden BA; Müller-Tidow C; Delwel HR; Serve H; Clapp DW; Hiebert SW
Ann Hematol; 2004 Jun; 83(6):329-30. PubMed ID: 15052372
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
Xu M; Li D; Lu Y; Chen GQ
Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein.
Fazi F; Racanicchi S; Zardo G; Starnes LM; Mancini M; Travaglini L; Diverio D; Ammatuna E; Cimino G; Lo-Coco F; Grignani F; Nervi C
Cancer Cell; 2007 Nov; 12(5):457-66. PubMed ID: 17996649
[TBL] [Abstract][Full Text] [Related]
18. AML1/RUNX1 fusion gene and t(5;21)(q13;q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia and monocytosis.
Liu S; Li C; Bo L; Dai Y; Xiao Z; Wang J
Cancer Genet Cytogenet; 2004 Jul; 152(2):172-4. PubMed ID: 15262442
[No Abstract] [Full Text] [Related]
19. RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.
DeKelver RC; Lewin B; Weng S; Yan M; Biggs J; Zhang DE
Leuk Lymphoma; 2014 Apr; 55(4):884-91. PubMed ID: 23772668
[TBL] [Abstract][Full Text] [Related]
20. Expression of AML/Runx and ETO/MTG family members during hematopoietic differentiation of embryonic stem cells.
Okumura AJ; Peterson LF; Lo MC; Zhang DE
Exp Hematol; 2007 Jun; 35(6):978-88. PubMed ID: 17533052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
